Cash flows from operating activities: | |
Net loss | -43.1M |
Adjustments to reconcile net loss to net cash used in operating activities: | |
Depreciation and amortization | 364.55K |
Retirement of fixed assets | 9.12K |
Non-cash gain on transfer of RXi common stock | |
Stock option and warrant expense | 5.4M |
Fair value adjustment on warrant liability | -939.67K |
Changes in assets and liabilities: | |
Receivable | 4.49M |
Interest receivable | 28.13K |
Prepaid expenses and other current assets | 781.01K |
Income taxes recoverable | |
Accounts payable | -3.25M |
Accrued expenses and other current liabilities | -4.64M |
Net cash used in operating activities | |
Cash flows from investing activities: | |
Net proceeds from sale of marketable securities | |
Proceeds from sale of assets held for sale | |
Proceeds from sale of unconsolidated subsidiary shares | |
Purchases of equipment and furnishings | -961.22K |
Net cash provided by investing activities | |
Cash flows from financing activities: | |
Net proceeds from exercise of stock options | |
Net cash provided by financing activities | |
Net increase in cash and cash equivalents | 36.61M |
Cash and cash equivalents at beginning of period | 22.26M |
Cash and cash equivalents at end of period | 58.88M |
Supplemental disclosure of cash flow information: | |
Cash received during the period as interest income |